Editorial: bacterial gut symbionts as live biotherapeutic agents in IBS—a rosy future despite potential long‐term safety concerns. Authorsʼ reply
- 15 January 2023
- journal article
- editorial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (3) , 347-348
Abstract
LINKED CONTENT: This article is linked to Quigley et al papers. To view these articles, visit https://doi.org/10.1111/apt.17310 and https://doi.org/10.1111/apt.17332Keywords
This publication has 9 references indexed in Scilit:
- Editorial: bacterial gut symbionts as live biotherapeutic agents in irritable bowel syndrome—a rosy future despite potential long‐term safety concernsAlimentary Pharmacology & Therapeutics, 2023
- Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2022
- A comparison of the composition and functions of the oral and gut microbiotas in Alzheimer’s patientsFrontiers in Cellular and Infection Microbiology, 2022
- Deciphering functional redundancy in the human microbiomeNature Communications, 2020
- Associations between gut microbiota and Alzheimer’s disease, major depressive disorder, and schizophreniaJournal of Neuroinflammation, 2020
- Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 12: suitability of taxonomic units notified to EFSA until March 2020EFSA Journal, 2020
- Protective effects of Akkermansia muciniphila on cognitive deficits and amyloid pathology in a mouse model of Alzheimer’s diseaseNutrition & Diabetes, 2020
- Gut Microbiota is Altered in Patients with Alzheimer’s DiseaseJournal of Alzheimer’s Disease, 2018
- Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiomeMovement Disorders, 2017